Analyst Price Target is $6.75
▲ +271.90% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Esperion Therapeutics in the last 3 months. The average price target is $6.75, with a high forecast of $16.00 and a low forecast of $2.50. The average price target represents a 271.90% upside from the last price of $1.82.
Current Consensus is
Moderate Buy
The current consensus among 6 polled investment analysts is to moderate buy stock in Esperion Therapeutics. This rating changed within the last month from a Hold consensus rating.
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Read More